SBD (Yemen)

Yemen SBDMA (Supreme Board of Drugs and Medical Appliances) — operating under the Ministry of Public Health and Population (MoPHP) Republic of Yemen — is the national regulatory authority for human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances across the Republic of Yemen. Yemen SBDMA operates under Law 1 of 2002 + Law 30 of 2011 + Law 31 of 2014 + Ministerial Decisions + SBDMA Decisions + Guidance Documents.

Yemen SBDMA organisational structure includes:

• Minister of Public Health and Population — political head appointed by the Council of Ministers.
• Deputy Minister + Undersecretary for Pharmaceutical Affairs.
• Chairman/Director General of SBDMA.
• Drug Registration Department — drug + biological + vaccine + biosimilar + generic-medicine registration.
• Pharmaceutical Inspection Department — GMP + GDP + GPP + GVP + GLP inspections of Yemeni + foreign manufacturing facilities.
• Medical Devices Department — medical-device + IVD registration + matériovigilance.
• Pharmacy Practice Department — pharmacy + pharmaceutical-establishment licensing.
• Cosmetics + Dietary Supplements Department — cosmetic-product + dietary-supplement notification.
• Controlled Substances Department — narcotics + psychotropics framework coordination with INCB + Ministry of Interior + Yemeni Customs.
• Central Drug Quality Control Laboratory (CDQCL) — central pharmaceutical QC laboratory; capacity substantially disrupted by conflict.
• Yemen Pharmacovigilance Centre — WHO PIDM-affiliated national PV centre (substantially disrupted by conflict; re-engaging via WHO support).
• International Affairs Section — WHO + Arab League + EMRO + UN-agency coordination.

Yemen's distinctive territorial-fragmentation context: since 2014/2015 the Republic of Yemen has experienced substantial territorial fragmentation. The Internationally Recognised Government (IRG — UN-recognised legitimate government) is headquartered in Aden + Riyadh (in-exile coordination), with substantial coverage of southern + eastern governorates (Aden + Hadramawt + Marib + Shabwa + Al-Mahra + Abyan + Lahij + parts of Taiz + Al-Bayda) + maintains operational MoPHP + SBDMA structures. Sana'a-based de facto authorities (Houthi/Ansar Allah-controlled) cover substantial north-western Yemen (Sana'a + Hodeidah + Sa'da + Hajjah + Amran + Dhamar + Ibb + parts of Taiz + Al-Mahwit + Raymah + Al-Jawf), with parallel operational MoPHP + SBDMA structures in Sana'a (the pre-2014 MoPHP HQ city). This territorial fragmentation creates substantial parallel pharmaceutical-regulatory frameworks: foreign manufacturers + UN-agency humanitarian operators + sponsors targeting all-of-Yemen must navigate parallel Aden-based IRG + Sana'a-based de facto authority pharmaceutical-regulatory engagement, with substantial operational differences in registration + inspection + procurement + customs + financial channels. This territorial-fragmentation duality is the most operationally significant feature of Yemeni pharmaceutical market access + humanitarian operations.

Yemen SBDMA is distinct from + complementary to: the Yemen Pharmacists Association (professional licensing body for individual pharmacists); the limited Yemeni domestic pharmaceutical-manufacturing industry (historically ~3-5 Yemeni-domestic manufacturers including Shibam Pharmaceutical Industries + Yedco + Modern Pharmaceutical Industries; substantially disrupted by conflict); Yemeni medical schools + pharmacy faculties (Sana'a University + University of Aden + Hadhramout University + University of Science and Technology Sana'a + Taiz University + Hodeidah University); and substantial UN-agency + NGO humanitarian healthcare operators including WHO + UNICEF + UNHCR + UNFPA + UNDP + WFP + ICRC + Yemeni Red Crescent + MSF + IRC + Première Urgence Internationale + Mercy Corps + Save the Children + Action Against Hunger + Norwegian Refugee Council + Danish Refugee Council supporting world's largest humanitarian-healthcare programme. Yemen's pharmaceutical environment is uniquely characterised by: world's largest humanitarian crisis context per UN OCHA assessments since 2015; substantial cholera + measles + COVID-19 + malnutrition + maternal-health emergency response; substantial UN-agency humanitarian healthcare dominance with WHO + UNICEF substantial procurement role; substantial Internally Displaced Persons (IDP) commitments (~4.5+ million IDPs); territorial-fragmentation parallel pharmaceutical-regulatory frameworks (IRG Aden + Sana'a de facto authorities); limited domestic pharmaceutical-manufacturing capacity; substantial pharmaceutical-import dependency primarily from India + Egypt + Jordan + Saudi Arabia + UAE; Arabic labelling environment; Climate Zone II coastal (Aden + Hodeidah + Mukalla) + Climate Zone IVa interior (Sana'a + Taiz + Ibb — Sana'a at ~2,250m elevation creating Climate Zone II conditions) pharmaceutical-stability environment with substantial humidity in coastal regions + dust + temperature extremes in interior.

Yemen SBDMA is an active League of Arab States Council of Arab Ministers of Health participant + a WHO Eastern Mediterranean Regional Office (EMRO) participant + maintains substantial operational cooperation channels with WHO + UNICEF + UNHCR + UNFPA + UNDP + WFP + ICRC + Yemeni Red Crescent + MSF for substantial humanitarian healthcare programmes including UN-led pooled procurement + cross-line humanitarian operations + historically maintained substantial bilateral cooperation with EMA + WHO + Indian CDSCO + Egyptian EDA + Jordanian JFDA + Saudi SFDA + UAE MoHAP reflecting Yemen's pharmaceutical-trade relationships.

Yemeni pharmaceutical regulation operates under a layered framework of Laws + Ministerial Decisions + SBDMA Decisions + Guidance Documents — with distinctive territorial-fragmentation parallel implementation:

• Law 1 of 2002 — Pharmacy Practice + Pharmaceutical Establishments framework.
• Law 30 of 2011 — Drugs + Pharmacies updated framework.
• Law 31 of 2014 — Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Ministerial Decisions + SBDMA Decisions on Drug Registration + Medical Devices + Cosmetics + Dietary Supplements + Pricing.
• Yemen SBDMA GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• Yemen SBDMA GDP Guide — substantively aligned with WHO + EU GDP.
• Yemen SBDMA GCP Guide — substantively aligned with ICH E6(R2).
• Yemen SBDMA GVP Guide — substantively aligned with ICH E2 + EU GVP.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + Indian Pharmacopoeia + Arab Pharmacopoeia.
• Yemeni National Essential Medicines List — substantial framework given substantial UN-agency + humanitarian-procurement dominance + WHO Essential Medicines List substantial alignment.
• Yemen SBDMA Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF.
• Yemen SBDMA Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• Yemen SBDMA Variations + 5-year Drug Registration Renewal framework.
• Territorial-Fragmentation Parallel Framework — distinctive parallel Aden-based IRG SBDMA + Sana'a-based de facto authority SBDMA implementation; foreign manufacturers + UN-agency humanitarian operators must navigate parallel pharmaceutical-regulatory engagement with operational differences in registration + inspection + procurement + customs + financial channels.
• UN-Agency Humanitarian Importation Framework — substantial framework given world's largest humanitarian crisis context + substantial WHO + UNICEF + UNHCR + UNFPA + WFP + ICRC + NGO humanitarian-imported medicines + devices; includes UN-led pooled procurement + cross-line humanitarian operations.

The Central Drug Quality Control Laboratory (CDQCL) is Yemen SBDMA's central pharmaceutical quality-control laboratory + capacity has been substantially disrupted by the post-2014/2015 conflict, with substantial WHO + UNICEF + bilateral-donor reconstruction-of-capacity assistance. Yemen's substantial UN-agency humanitarian-procurement dominance creates substantial parallel humanitarian quality-verification frameworks operated by WHO + UNICEF + UNHCR + UNFPA + WFP + ICRC procurement + quality-assurance teams.

• ISO/IEC 17025 — CDQCL historically pursued ISO/IEC 17025 scope expansion; capacity substantially disrupted by conflict; rebuilding via WHO + UNICEF + bilateral-donor support.
• WHO PQ-Lab Aspiration — CDQCL historically pursued WHO PQ-Lab dialogue prior to conflict disruption; long-term aspiration.
• Vaccine lot release — CDQCL conducts vaccine lot-release testing for Yemen SBDMA + Yemeni Expanded Programme on Immunization including substantial UNICEF + WHO + Gavi-supported vaccine procurement; substantial UNICEF + WHO quality-assurance support given conflict-disrupted capacity.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance + targeted enforcement testing; substantially constrained by conflict context.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing.
• Counterfeit-medicine forensics — forensic analytical support for Yemen SBDMA + Ministry of Interior + Yemeni Customs investigations + WHO Global Surveillance & Monitoring System contributions; substantial conflict-environment supply-chain disruption + cross-border smuggling counterfeit risks.
• WHO + UNICEF Humanitarian Quality Verification — substantial parallel humanitarian quality-verification framework operated by WHO + UNICEF + UNHCR + UNFPA + WFP + ICRC procurement + quality-assurance teams given Yemen's substantial UN-agency humanitarian-procurement dominance; WHO + UNICEF substantial capacity-building support to CDQCL.
• Capacity-building — substantial WHO + Arab League + EMA + USP + bilateral-donor capacity-building programmes + training for Yemeni pharmaceutical analysts + CDQCL reconstruction support.
• GMP Inspectorate support — provides scientific + technical support for Yemen SBDMA Pharmaceutical Inspection Department GMP inspections of Yemeni + foreign manufacturing facilities; substantially constrained by conflict context for foreign-manufacturing inspections.
• Yemeni domestic manufacturer support — supports historical ~3-5 Yemeni-domestic manufacturers (Shibam Pharmaceutical Industries + Yedco + Modern Pharmaceutical Industries) rebuilding post-conflict capacity.
• Humanitarian medicine quality — distinctive substantial role given substantial UN-agency + NGO humanitarian-procured medicines requiring post-market quality verification + cross-line humanitarian operations quality-assurance coordination.

Yemen SBDMA medical-device + IVD regulation operates under Yemen SBDMA Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF. Foreign manufacturers must appoint a Yemeni Authorised Representative. Yemen's medical-device market is dominated by foreign manufacturers + substantial UN-agency + NGO humanitarian-imported devices for IDP + vulnerable-population healthcare.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF; IVDs classified under separate framework.
• Yemeni Authorised Representative — Yemen-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + Yemen SBDMA regulatory interface.
• ISO 13485:2016 — recognised by Yemen SBDMA as QMS evidence framework; Yemen-specific overlay required.
• Reliance pathways — Yemen SBDMA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence; CE Mark + FDA particularly central.
• Arab League Medical Devices Harmonisation — Yemen participates in Council of Arab Ministers of Health medical-device harmonisation.
• UN-Agency Medical Device Humanitarian Importation (Dominant Pathway) — substantial framework given WHO + UNICEF + UNHCR + UNFPA + WFP + ICRC + NGO humanitarian medical-device + IVD importation; the dominant medical-device-supply pathway in Yemen given world's largest humanitarian crisis context.
• IRG / Sana'a Parallel Medical Device Procurement — distinctive parallel IRG Aden-based + Sana'a-based de facto authority medical-device procurement reflecting territorial-fragmentation reality.
• Post-market vigilance — Yemen SBDMA operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes; substantially constrained by conflict context.
• IVD Réactovigilance — Yemen SBDMA operates IVD réactovigilance reflecting Yemen's clinical-laboratory infrastructure including teaching hospitals + UN-agency-supported field laboratories.
• Cosmetic Notification — cosmetics require Yemen SBDMA Cosmetic Notification + Arabic labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU-aligned framework.
• Dietary Supplement Registration — Yemen SBDMA Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Humanitarian Device Importation — substantial UN-agency + NGO humanitarian medical-device + IVD importation framework for substantial humanitarian healthcare programmes including cross-line humanitarian operations.
• Importation Permit — Yemen SBDMA Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering Yemen; coordination with Yemeni Customs + parallel IRG / Sana'a customs processing.

Yemen SBDMA operates the Yemen Pharmacovigilance Centre. Yemen is a WHO Programme for International Drug Monitoring (PIDM) member + historically contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC) (capacity substantially disrupted by conflict; re-engaging via WHO + UMC support). The Yemen Pharmacovigilance Centre coordinates with university teaching hospitals + UN-agency + NGO humanitarian-healthcare operators. Yemen's pharmacovigilance is uniquely shaped by world's largest humanitarian crisis context + substantial IDP + vulnerable-population vaccine + essential-medicines safety surveillance commitments + substantial cholera + measles + COVID-19 + malnutrition emergency response + substantial counterfeit + substandard medicine surveillance commitments.

• Yemen Pharmacovigilance Centre — coordinated by Yemen SBDMA.
• WHO PIDM Member — Yemen is a WHO PIDM member; historically contributes ADR data to VigiBase via Uppsala Monitoring Centre; re-engaging via WHO + UMC support given conflict-disrupted capacity.
• Yemeni PV Network — coordinated national network with effector centres in major Yemeni university teaching hospitals (Al-Thawra Modern General Hospital — Sana'a, Al-Sabeen Maternal Hospital — Sana'a, Al-Kuwait University Hospital — Sana'a, Aden General Hospital, Al-Naqib Hospital — Aden, Al-Mukalla General Hospital, Taiz Republican Hospital, Hodeidah Republican Hospital, Ibb General Hospital) + Marketing Authorisation Holders + UN-agency humanitarian healthcare operators + parallel IRG / Sana'a operational frameworks.
• ADR Reporting — Yemen SBDMA operates ADR reporting via Yemen SBDMA portal where capacity permits; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — Yemen SBDMA accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); Yemen SBDMA-specific submission timeline.
• Risk Management Plans (RMP) — Yemen SBDMA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — Yemen Pharmacovigilance Centre operates targeted active-surveillance programmes for COVID-19 vaccines + childhood immunisation + cholera vaccine + measles vaccine where capacity permits; substantial WHO + UNICEF support.
• IDP + vulnerable-population PV — distinctive substantial commitments for ~4.5+ million Internally Displaced Persons + vulnerable-population vaccine + essential-medicines safety surveillance coordinated with UNHCR + UNICEF + UNFPA + WHO + ICRC + cross-line humanitarian operations.
• AEFI Surveillance — Yemeni vaccine adverse-event surveillance aligned with WHO methodology; central to Yemeni Expanded Programme on Immunization + substantial UNICEF + Gavi + WHO-supported immunisation campaigns including polio + measles + cholera + COVID-19 catch-up campaigns.
• Cholera + Measles + COVID-19 outbreak response — distinctive substantial role given world's largest cholera epidemic (2016-onwards) + recurrent measles + COVID-19 outbreaks; substantial WHO + UNICEF + MSF + ICRC outbreak-response coordination.
• Matériovigilance + Cosmétovigilance — Yemen SBDMA operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — distinctive substantial role given conflict-environment supply-chain disruption + cross-border smuggling + Yemen's geographic position creating substantial counterfeit + substandard medicine quality risks.
• Arab League Pharmacovigilance — Yemen participates in Arab League Council of Arab Ministers of Health pharmacovigilance harmonisation.

• WHO EMRO Participant — Yemen SBDMA is an active WHO Eastern Mediterranean Regional Office (EMRO) participant; substantial WHO + UN-agency humanitarian healthcare cooperation including world's largest humanitarian-response operations.
• WHO PIDM Member — Yemen historically contributes ADR data to VigiBase via Uppsala Monitoring Centre; re-engaging via WHO + UMC support.
• WHO PQ Procurement Recipient — Yemen is one of the largest WHO + UNICEF + UNHCR + UNFPA + WFP + ICRC humanitarian-procurement recipients globally for the world's largest humanitarian crisis response since 2015.
• Arab League Council of Arab Ministers of Health Participant — Yemen SBDMA is an active pharmaceutical-harmonisation participant alongside Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + Lebanese MoPH + Iraq MoH + Syria MoH + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• EMA Cooperation — Yemen SBDMA historically maintains EU reliance practice for high-end + biologicals + specialty pharmaceuticals.
• FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS Bilateral — Yemen SBDMA maintains Stringent Regulatory Authority reliance practice.
• Indian CDSCO Bilateral — distinctive substantial trade-driven cooperation reflecting India being the dominant pharmaceutical import source for Yemen; CDSCO-approved generics dominate substantial Yemeni public-sector + UN-agency humanitarian procurement categories.
• Egyptian EDA Bilateral — substantial trade-driven cooperation reflecting Egypt's substantial pharmaceutical export trade with Yemen.
• Jordanian JFDA Bilateral — substantial trade-driven cooperation reflecting Jordan's substantial pharmaceutical export trade with Yemen.
• Saudi SFDA Bilateral — substantial trade-driven cooperation reflecting Saudi Arabia's substantial pharmaceutical export trade with Yemen + substantial humanitarian-procurement coordination role.
• UAE MoHAP Bilateral — substantial trade-driven cooperation reflecting UAE's substantial humanitarian-logistics + procurement hub role for Yemen response via Jebel Ali Free Zone + International Humanitarian City Dubai.
• Oman MoH Cooperation — substantial neighbour-cooperation reflecting Oman's substantial humanitarian-logistics hub role for Yemen response + cross-border humanitarian operations via Mazyona border crossing.
• PIC/S Cooperation — Yemen SBDMA GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7; PIC/S dialogue historically maintained.
• ICH Observer Practice — ICH guidelines implemented in Yemeni regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4 where capacity permits.
• ICDRA + EMRO participation — historical International Conference of Drug Regulatory Authorities + active WHO EMRO participant.
• UN-Agency Humanitarian Cooperation (Dominant Framework) — substantial cooperation with WHO + UNICEF + UNHCR + UNFPA + WFP + UNDP + ICRC + Yemeni Red Crescent + MSF + IRC + Première Urgence Internationale + Mercy Corps + Save the Children + Action Against Hunger + Norwegian Refugee Council + Danish Refugee Council for substantial humanitarian healthcare programmes; among the most substantial UN-agency humanitarian pharmaceutical operational frameworks globally including cross-line humanitarian operations + UN-led pooled procurement.
• Donor Cooperation — substantial bilateral cooperation with USAID + EU ECHO + UK FCDO + Germany BMZ/GIZ + Japan JICA + Saudi Development Fund + UAE Aid + Kuwait Fund + World Bank + Islamic Development Bank for humanitarian healthcare + reconstruction programming.

• Territorial-fragmentation parallel-registration strategy missed — most operationally significant feature of Yemeni pharmaceutical market access frequently overlooked; foreign manufacturers + UN-agency humanitarian operators targeting all-of-Yemen must navigate parallel IRG Aden-based SBDMA + Sana'a-based de facto authority SBDMA engagement with substantially differing operational timelines + administrative procedures + customs + financial channels.
• Yemeni Authorised Representative not properly designated — application rejected at Yemen SBDMA intake or post-approval compliance failure; Yemeni Authorised Representative must be Yemen-resident legal entity with appropriate licensure; parallel IRG / Sana'a-area-appropriate Authorised Representative may be required.
• Arabic labelling deficiencies — Arabic required for all-of-Yemen market access; many applicants provide insufficient Arabic-language patient leaflet content.
• Yemen SBDMA GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Yemen-specific Yemen SBDMA GMP clarifications.
• Yemen climate-zone stability data missing — Yemen is Climate Zone II coastal (Aden / Hodeidah / Mukalla) + Climate Zone IVa interior (Taiz / Ibb / parts of Sana'a Governorate) with distinctive Sana'a city Climate Zone II conditions due to ~2,250m elevation; requires substantial zonal-specific stability data including humidity + dust + temperature-extreme considerations.
• WHO PQ reliance under-utilised — WHO-PQ-approved products eligible for accelerated Yemen SBDMA review (60-120 day target); substantially under-utilised by many applicants despite Yemen's substantial UN-agency humanitarian-procurement dominance.
• UN-Agency humanitarian procurement pathway not leveraged — substantial WHO + UNICEF + UNHCR + UNFPA + WFP + ICRC + UN-led pooled procurement opportunity for substantial humanitarian healthcare programmes — the dominant pharmaceutical-supply pathway in Yemen — frequently overlooked by foreign manufacturers targeting only private-sector Yemeni market.
• Cross-line humanitarian operations distinct regulatory environment not understood — substantial cross-line humanitarian operations between IRG-controlled + Sana'a-controlled territory operate in distinct operational regulatory environment; substantial coordination with OCHA + WHO + UNICEF + UNHCR + INGO Forum required.
• EMA + SRA reliance under-utilised — Yemen SBDMA operates substantial reliance on EMA + Stringent Regulatory Authority decisions.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised.
• Trade-partner reliance (India CDSCO / Egypt EDA / Jordan JFDA / Saudi SFDA / UAE MoHAP) under-utilised — distinctive substantial trade-driven reliance reflecting Yemen's pharmaceutical-import trade relationships; particularly substantial for Indian-CDSCO-approved generics dominating Yemeni public-sector + UN-agency humanitarian procurement categories.
• Bioequivalence centres + biowaiver — Yemen SBDMA BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Registration under-utilised; 60-120 calendar day target; substantial humanitarian-emergency response acceleration available.
• Cholera + Measles + COVID-19 outbreak response opportunity not leveraged — substantial WHO + UNICEF + MSF + ICRC outbreak-response procurement opportunity given recurrent epidemic context frequently overlooked.
• UAE Jebel Ali + Dubai International Humanitarian City + Oman humanitarian-logistics hub leveraging missed — substantial humanitarian-logistics + procurement hub coordination opportunity via UAE + Oman.
• Counterfeit + substandard medicine quality risks under-monitored — Yemen's conflict-environment supply-chain disruption + cross-border smuggling create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance frequently overlooked.
• Variations strategy not planned — variations procedure substantively similar to EU but with Yemen-specific timelines + fee structure + conflict-environment administrative delays; parallel IRG / Sana'a variations procedures.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration; parallel IRG / Sana'a renewal procedures.

V5 Ultimate provides the operational infrastructure Yemeni + foreign-supplier sites + UN-agency humanitarian operators need for Law 1 of 2002 + Law 30 of 2011 + Yemen SBDMA GMP + Medical Devices framework + WHO PQ reliance + EMA + SRA reliance + Arab League + Indian CDSCO + Egyptian EDA + Jordanian JFDA + Saudi SFDA + UAE MoHAP trade-partner reliance + Yemen Pharmacovigilance Centre + UN-agency humanitarian procurement (the dominant pathway) + cross-line humanitarian operations + parallel IRG / Sana'a operational frameworks.

• Yemen SBDMA GMP control framework — PIC/S + EU GMP + ICH Q7 + WHO TRS 986 Annex 2-aligned controls with ALCOA+ data-integrity + Yemen-specific clarifications + Climate Zone II + IVa stability monitoring including coastal humidity + interior temperature-extreme + Sana'a city elevation conditions.
• Yemen SBDMA Registration dossier packaging — Yemen CTD-aligned dossier structure with Yemen Module 1 specifics + Module 3 stability + Arabic patient leaflet + Authorised Representative declarations + Law 1 of 2002 + Law 30 of 2011 framework.
• IRG / Sana'a parallel Registration workflow — distinctive parallel IRG Aden-based + Sana'a-based de facto authority Drug Registration packaging reflecting territorial-fragmentation reality — most operationally significant feature of Yemeni pharmaceutical market access frequently overlooked.
• WHO PQ reliance workflow — WHO-PQ-approved product packaging with reduced dossier + accelerated Yemen SBDMA review (60-120 day target); substantially central to Yemeni humanitarian pharmaceutical operations.
• EMA + SRA reliance workflow — Yemen SBDMA-EMA + Yemen SBDMA-FDA + Yemen SBDMA-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging.
• Trade-partner reliance workflow (India CDSCO / Egypt EDA / Jordan JFDA / Saudi SFDA / UAE MoHAP) — distinctive substantial trade-driven reliance packaging reflecting Yemen's substantial pharmaceutical-import trade relationships; particularly substantial for Indian-CDSCO-approved generics dominating Yemeni public-sector + UN-agency humanitarian procurement categories.
• UN-Agency humanitarian procurement workflow (Dominant Pathway) — WHO + UNICEF + UNHCR + UNFPA + WFP + UNDP + ICRC + UN-led pooled procurement framework packaging for substantial humanitarian healthcare programmes — the dominant pharmaceutical-supply pathway in Yemen given world's largest humanitarian crisis context.
• Cross-line humanitarian operations workflow — distinct operational regulatory environment packaging for cross-line humanitarian operations between IRG-controlled + Sana'a-controlled territory + OCHA + WHO + UNICEF + UNHCR + INGO Forum coordination.
• Cholera + Measles + COVID-19 outbreak response workflow — substantial WHO + UNICEF + MSF + ICRC outbreak-response procurement framework packaging given recurrent epidemic context including world's largest cholera epidemic since 2016.
• UAE Jebel Ali + Dubai International Humanitarian City + Oman humanitarian-logistics workflow — substantial humanitarian-logistics + procurement hub coordination packaging via UAE + Oman for Yemen response.
• Yemeni Authorised Representative workflow — foreign-manufacturer Yemeni Authorised Representative designation + role-management + parallel IRG / Sana'a-area-appropriate representation + Yemen-specific post-market surveillance.
• Yemeni clinical-trial workflow — Yemen SBDMA CTA + Sana'a University / University of Aden / Hadhramout University / University of Science and Technology Sana'a / Taiz / Hodeidah University IRB coordination + Yemeni SUSAR reporting via Yemen Pharmacovigilance Centre.
• Yemen Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic ICSR + Yemeni PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + IDP + vulnerable-population safety surveillance + cholera + measles + COVID-19 outbreak surveillance.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging across IRG / Sana'a frameworks.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — Yemen SBDMA frameworks dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Counterfeit + substandard medicine surveillance workflow — Yemen's conflict-environment supply-chain disruption + cross-border smuggling monitoring + WHO Global Surveillance & Monitoring System integration.
• Essential Medicines + Vital Medicines accelerated workflow — Yemeni National Essential Medicines List + WHO Essential Medicines List + public-health emergency product packaging + humanitarian-emergency response acceleration.
• Arab League + Arabian Peninsula + trade-partner regional bridging — for companies operating across Arab League + Arabian Peninsula + Indian + Egyptian + Jordanian + Saudi + UAE trade-partner jurisdictions, V5 surfaces Yemen SBDMA + Saudi SFDA + UAE MoHAP + Oman MoH + Egypt EDA + Jordan JFDA + India CDSCO harmonised dossier-element reuse alongside national-specific extensions.